Targeting fibroblast growth factor pathways in endometrial cancer

Current Problems in Cancer

Volumn 41, Issue 1, 2017, Pages 37-47

  Winterhoff, Boris ^a   Konecny, Gottfried E ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Endometrial cancer; Fibroblast growth factor

Indexed keywords

BRIVANIB; DOVITINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; LENVATINIB; NINTEDANIB; PONATINIB; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ARTICLE; CLINICAL TRIAL (TOPIC); ENDOMETRIUM CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENDOMETRIUM TUMOR; FEMALE; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 85009350703     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2016.11.002     Document Type: Article

References (81)

1. 1 National Cancer Institute. Cancer of the endometrium. SEER Stat Fact Sheets; 2015.
2. 2 National Comprehensive Cancer Network. Uterine neoplasms, version 2.2015. http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf; 2015.
3. 3 Bakkum-Gamez, J.N., Gonzalez-Bosquet, J., Laack, N.N., Mariani, A., Dowdy, S.C., Current issues in the management of endometrial cancer. Mayo Clin Proc 83:1 (2008), 97–112.
4. 4 Carlson, M.J., Thiel, K.W., Leslie, K.K., Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health 6 (2014), 429–435.
5. 5 Duggan, B.D., Felix, J.C., Muderspach, L.I., Tourgeman, D., Zheng, J., Shibata, D., Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 86:16 (1994), 1216–1221.
6. 6 Risinger, J.I., Berchuck, A., Kohler, M.F., Watson, P., Lynch, H.T., Boyd, J., Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53:21 (1993), 5100–5103.
7. 7 Yeramian, A., Moreno-Bueno, G., Dolcet, X., et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene 32:4 (2013), 403–413.
8. 8 Byron, S.A., Gartside, M.G., Wellens, C.L., et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68:17 (2008), 6902–6907.
9. 9 Lee, P.S., Secord, A.A., Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway. Cancer Treat Rev 40:4 (2014), 507–512.
10. 10 Byron, S.A., Loch, D.C., Pollock, P.M., Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. Int J Gynecol Cancer 22:9 (2012), 1517–1526.
11. 11 Dutt, A., Salvesen, H.B., Chen, T.H., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 105:25 (2008), 8713–8717.
12. 12 Pollock, P.M., Gartside, M.G., Dejeza, L.C., et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26:50 (2007), 7158–7162.
13. 13 Zagouri, F., Bozas, G., Kafantari, E., et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?. Obstet Gynecol Int, 2010, 2010, 749579.
14. 14 Okuda, T., Sekizawa, A., Purwosunu, Y., et al. Genetics of endometrial cancers. Obstet Gynecol Int, 2010, 2010, 984013.
15. 15 Lax, S.F., Kendall, B., Tashiro, H., Slebos, R.J., Hedrick, L., The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:4 (2000), 814–824.
16. 16 Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., et al. Integrated genomic characterization of endometrial carcinoma. Nature 497:7447 (2013), 67–73.
17. 17 Itoh, N., Ornitz, D.M., Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149:2 (2011), 121–130.
18. 18 Greulich, H., Pollock, P.M., Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 17:5 (2011), 283–292.
19. 19 Beenken, A., Mohammadi, M., The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8:3 (2009), 235–253.
20. 20 Holzmann, K., Grunt, T., Heinzle, C., et al. Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer. J Nucleic Acids, 2012, 2012, 950508.
21. 21 Dieci, M.V., Arnedos, M., Andre, F., Soria, J.C., Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 3:3 (2013), 264–279.
22. 22 Furdui, C.M., Lew, E.D., Schlessinger, J., Anderson, K.S., Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 21:5 (2006), 711–717.
23. 23 Mohammadi, M., Dionne, C.A., Li, W., et al. Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature 358:6388 (1992), 681–684.
24. 24 Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y., Krasnow, M.A., Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the drosophila airways. Cell 92:2 (1998), 253–263.
25. 25 Kovalenko, D., Yang, X., Nadeau, R.J., Harkins, L.K., Friesel, R., Self-inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J Biol Chem 278:16 (2003), 14087–14091.
26. 26 Wakioka, T., Sasaki, A., Kato, R., et al. Spred is a sprouty-related suppressor of ras signalling. Nature 412:6847 (2001), 647–651.
27. 27 Yang, R.B., Ng, C.K., Wasserman, S.M., Komuves, L.G., Gerritsen, M.E., Topper, J.N., A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling. J Biol Chem 278:35 (2003), 33232–33238.
28. 28 Kwabi-Addo, B., Ozen, M., Ittmann, M., The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11:4 (2004), 709–724.
29. 29 Takahashi, J.A., Fukumoto, M., Igarashi, K., Oda, Y., Kikuchi, H., Hatanaka, M., Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76:5 (1992), 792–798.
30. 30 Lieu, C., Heymach, J., Overman, M., Tran, H., Kopetz, S., Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 17:19 (2011), 6130–6139.
31. 31 Pepper, M.S., Ferrara, N., Orci, L., Montesano, R., Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:2 (1992), 824–831.
32. 32 Turner, N., Pearson, A., Sharpe, R., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:5 (2010), 2085–2094.
33. 33 Wang, Y., Becker, D., Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 3:8 (1997), 887–893.
34. 34 Birrer, M.J., Johnson, M.E., Hao, K., et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25:16 (2007), 2281–2287.
35. 35 Giavazzi, R., Sennino, B., Coltrini, D., et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 162:6 (2003), 1913–1926.
36. 36 Casanovas, O., Hicklin, D.J., Bergers, G., Hanahan, D., Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:4 (2005), 299–309.
37. 37 Salven, P., Lymboussaki, A., Heikkila, P., et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:1 (1998), 103–108.
38. 38 Moreira, I.S., Fernandes, P.A., Ramos, M.J., Vascular endothelial growth factor (VEGF) inhibition—a critical review. Anticancer Agents Med Chem 7:2 (2007), 223–245.
39. 39 Kamat, A.A., Merritt, W.M., Coffey, D., et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13:24 (2007), 7487–7495.
40. 40 Goel, H.L., Mercurio, A.M., VEGF targets the tumour cell. Nat Rev Cancer 13:12 (2013), 871–882.
41. 41 Gadducci, A., Sergiampietri, C., Guiggi, I., Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. Gynecol Endocrinol 29:9 (2013), 811–816.
42. 42 Schmid, B.C., Oehler, M.K., Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers. Curr Treat Options Oncol, 16(1), 2015, 318, 10.1007/s11864-014-0318-0.
43. 43 Korc, M., Friesel, R.E., The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 9:5 (2009), 639–651.
44. 44 Byron, S.A., Gartside, M., Powell, M.A., et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One, 7(2), 2012, e30801.
45. 45 Stelloo, E., Bosse, T., Nout, R.A., et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: a TransPORTEC initiative. Mod Pathol 28:6 (2015), 836–844.
46. 46 Krakstad, C., Birkeland, E., Seidel, D., et al. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS One, 7(12), 2012, e52795.
47. 47 Gatius, S., Velasco, A., Azueta, A., et al. FGFR2 alterations in endometrial carcinoma. Mod Pathol 24:11 (2011), 1500–1510.
48. 48 Spaans, V.M., Trietsch, M.D., Crobach, S., et al. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One, 9(3), 2014, e93451.
49. 49 Ibrahimi, O.A., Eliseenkova, A.V., Plotnikov, A.N., Yu, K., Ornitz, D.M., Mohammadi, M., Structural basis for fibroblast growth factor receptor 2 activation in apert syndrome. Proc Natl Acad Sci U S A 98:13 (2001), 7182–7187.
50. 50 Ibrahimi, O.A., Zhang, F., Eliseenkova, A.V., Itoh, N., Linhardt, R.J., Mohammadi, M., Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 13:19 (2004), 2313–2324.
51. 51 Yu, K., Herr, A.B., Waksman, G., Ornitz, D.M., Loss of fibroblast growth factor receptor 2 ligand-binding specificity in apert syndrome. Proc Natl Acad Sci U S A 97:26 (2000), 14536–14541.
52. 52 Peng, W.X., Kudo, M., Fujii, T., Teduka, K., Naito, Z., Altered expression of fibroblast growth factor receptor 2 isoform IIIc: Relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation. Int J Clin Exp Pathol 7:3 (2014), 1069–1076.
53. 53 Konecny, G.E., Kolarova, T., O'Brien, N.A., et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther 12:5 (2013), 632–642.
54. 54 Byron, S.A., Chen, H., Wortmann, A., et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia 15:8 (2013), 975–988.
55. 55 Fujimoto, J., Hori, M., Ichigo, S., Tamaya, T., Expression of basic fibroblast growth factor and its mRNA in uterine endometrial cancers. Invasion Metastasis 15:5–6 (1995), 203–210.
56. 56 Soufla, G., Sifakis, S., Spandidos, D.A., FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium. Cancer Lett 259:2 (2008), 146–155.
57. 57 Dai, H., Zhao, S., Xu, L., Chen, A., Dai, S., Expression of efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue. Oncol Rep 23:3 (2010), 795–799.
58. 58 Fujimoto, J., Hori, M., Ichigo, S., Tamaya, T., Expressions of the fibroblast growth factor family (FGF-1, -2 and -4) mRNA in endometrial cancers. Tumour Biol 17:4 (1996), 226–233.
59. 59 Harding, T.C., Long, L., Palencia, S., et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med, 5(178), 2013, 178ra39.
60. 60 Harding TC, Palencia S, Long L, et al. Preclinical efficacy of FP-1039 (FGFR1:Fc) in endometrial carcinoma modelswith activating mutations in FGFR2. AACR Annual Meeting; 2010. Abstract 2597.
61. 61 Ahmed, Z., Schuller, A.C., Suhling, K., Tregidgo, C., Ladbury, J.E., Extracellular point mutations in FGFR2 elicit unexpected changes in intracellular signalling. Biochem J 413:1 (2008), 37–49.
62. 62 Wilkie, A.O., Patey, S.J., Kan, S.H., van den Ouweland, A.M., Hamel, B.C., FGFs, their receptors, and human limb malformations: clinical and molecular correlations. Am J Med Genet 112:3 (2002), 266–278.
63. 63 Gozgit, J.M., Squillace, R.M., Wongchenko, M.J., et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol 71:5 (2013), 1315–1323.
64. 64 Powell, M.A., Sill, M.W., Goodfellow, P.J., et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol 135:1 (2014), 38–43.
65. 65 Dizon, D.S., Sill, M.W., Schilder, J.M., et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol 135:3 (2014), 441–445.
66. 66 Konecny, G.E., Finkler, N., Garcia, A.A., et al. Phase 2 study of second-line dovitinib (TKI258) in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or -nonmutated advanced and/or metastatic endometrial cancer. Eur Soc Med Oncol, 2014 [Abstract LBA27].
67. 67 Konecny, G.E., Finkler, N., Garcia, A.A., et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 16:6 (2015), 686–694.
68. 68 Hong, D.S., Kurzrock, R., Wheler, J.J., et al. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res 21:21 (2015), 4801–4810.
69. 69 Vergote, I., Teneriello, M., Powell, M.A., et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol, 31(suppl), 2013 [ASCO Annual Meeting Abstracts, Abstract 5520].
70. 70 Funahashi, Y., Penson, R.T., Powell, M.A., et al. Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer. J Clin Oncol, 31(suppl), 2013 [ASCO Annual Meeting Abstracts, Abstract 5591].
71. 71 Gozgit, J.M., Wong, M.J., Moran, L., et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11:3 (2012), 690–699.
72. 72 Castonguay, V., Lheureux, S., Welch, S., et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the princess margaret, chicago and california consortia. Gynecol Oncol 134:2 (2014), 274–280.
73. 73 Nimeiri, H.S., Oza, A.M., Morgan, R.J., et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the chicago, PMH, and california phase II consortia. Gynecol Oncol 117:1 (2010), 37–40.
74. 74 McMeekin, D.S., Sill, M.W., Benbrook, D., et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a gynecologic oncology group study. Gynecol Oncol 105:2 (2007), 508–516.
75. 75 McMeekin, D.S., Sill, M.W., Darcy, K.M., et al. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol 127:2 (2012), 356–361.
76. 76 Aghajanian, C., Sill, M.W., Darcy, K.M., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. J Clin Oncol 29:16 (2011), 2259–2265.
77. 77 Alvarez, E.A., Brady, W.E., Walker, J.L., et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 129:1 (2013), 22–27.
78. 78 Coleman, R.L., Sill, M.W., Lankes, H.A., et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 127:3 (2012), 538–543.
79. 79 Wilkie, A.O., Slaney, S.F., Oldridge, M., et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with crouzon syndrome. Nat Genet 9:2 (1995), 165–172.
80. 80 Li, Y., Mangasarian, K., Mansukhani, A., Basilico, C., Activation of FGF receptors by mutations in the transmembrane domain. Oncogene 14:12 (1997), 1397–1406.
81. 81 Lorenzi, M.V., Castagnino, P., Chen, Q., Chedid, M., Miki, T., Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations. Oncogene 15:7 (1997), 817–826.